|Articles|November 15, 2016

Physicians Want Strong FDA Biosimilar Naming

The Biologics Prescribers Collaborative has released findings from a physician’s survey about the FDA’s proposed biosimilar naming guidelines.

The Biologics Prescribers Collaborative has released findings from a physician’s survey about the FDA’s proposed biosimilar naming guidelines. According to the survey, 80 percent of physicians prefer a meaningful four-letter suffix that notes the biosimilar manufacturer’s name as opposed to a random four-letter suffix.
Read the full release here

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.